"Globally Renowned for Expertise in Liver Care and Research TLI is a one-of-a-kind facility that encompasses one of the few dedicated and freestanding clinic (Texas Liver Consultants, TLC) and research facilities (American Research Corporation, ARC). The most advanced research in viral hepatitis, alcoholic and non-alcoholic fatty liver disease, autoimmune liver disease, and cirrhosis is conducted at this facility, which has been recognized internationally for its contributions to the field of liver diseases."

During the past decade, Texas Liver Institute conducted 61 clinical trials. In the 10-year time frame, 61 clinical trials started and 23 clinical trials were completed, i.e. on average, 37.7% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 16 clinical trials were completed. i.e. 59.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Liver Institute" #1 sponsor was "Bristol-Myers Squibb" with 16 trials, followed by "Gilead Sciences" with 10 trials sponsored, "Celgene" with 4 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored and "Galectin Therapeutics Inc." with 4 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Liver Institute" #1 collaborator was "Dr. Naga Chalasani, MD, Indiana University" with 1 trials as a collaborator, "Dr. Stephen A. Harrison, MD, Brooke Army Medical Center" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator, "Loxo Oncology, Inc." with 1 trials as a collaborator and "Pharmaceutical Research Associates" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Texas Liver Institute" are "Hepatic Impairment" (14 trials), "Hepatitis C" (10 trials), "Hepatitis C Virus Infection" (5 trials), "Non-Alcoholic Steatohepatitis" (4 trials) and "Cirrhosis" (3 trials). Many other conditions were trialed in "Texas Liver Institute" in a lesser frequency.

Most popular intervention types in "Texas Liver Institute" are "Drug" (63 trials), "Other" (4 trials), "Biological" (1 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Ribavirin" (5 trials), "Daclatasvir" (4 trials), "BMS-986263" (3 trials) and "RBV" (3 trials). Other intervention names were less common.

The vast majority of trials in "Texas Liver Institute" are 70 trials for "All" genders.

Currently, there are NaN active trials in "Texas Liver Institute". undefined are not yet recruiting, 7 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 49 completed trials in Texas Liver Institute, 1 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Liver Institute, 33 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".